El Prof. Nils Thoennissen es un especialista internacional en cáncer, enfermedades crónico degenerativas y medicina regenerativa con más de 20 años de experiencia en medicina basada en evidencia y 14 años de experiencia clínica en hemoterapia. Es autor de 40 publicaciones científicas en revistas revisadas por pares y ha sido galardonado con 6 premios. Ha recibido formación de posgrado en la Universidad de Münster, la Facultad de Medicina de la Universidad de Cardiff, la Universidad de Mainz y el Centro Médico Cedars-Sinai. Actualmente ocupa el cargo de director médico de CBC Health y ha ocupado cargos anteriores como médico jefe en el Hospital St. George, el Centro Médico Kloster Paradies y el Centro Médico Universitario Hamburg-Eppendorf.
Accommodation is not included
Traslado aeropuerto-clínica-aeropuerto
CBC Health is a day-clinic where the patient will get his treatment and will be released every day to the hotel.
Symptoms after a stroke: cord blood and stem cells prove their curative effect.
According to statistics, 20 to 25% of patients who survive a stroke die within the following four weeks. All others have various degrees of brain damage, ranging from mild problems in everyday life to severe symptoms requiring long-term care. Is there a way to avoid this? New methods of regenerative therapy suggest that there is.
Umbilical cord blood - therapies and stem cells for a better prognosis
As a result of a stroke, there is reactive inflammation in the brain caused by the damaged tissue. Unfortunately, this impairs the patient's recovery process and can also affect adjacent healthy brain tissue.
Here, recent meta-analyses in the field of regenerative medicine from 2022 show that it is possible to optimize prognosis after stroke has occurred (Paton MCB et al, Cytotherapy, 2022). Intravenous delivery of umbilical cord blood (UCB) may lead to improvement in this case, as the primitive cells contained in UCB may help inflammation in the brain to subside more quickly and rescue neurons that are about to die. In addition, UCB provides powerful growth factors and molecules that stimulate natural healing processes such as the formation of new synapses and neuronal circuitry.
While the efficacy of regenerative stem cell therapy has not been fully researched, there are no concerns about unexpected safety risks associated with its use. Most positively, there are no reports of immunological rejection, and UCB has an even lower risk profile than traditional blood transfusion in adults. These findings give stroke patients reason to hope for a better future.
Coordinador médico personal
Organización de viajes médicos: reserva de billetes de avión y habitaciones de hotel a precios especiales para socios
La protección de los intereses de pacientes durante un viaje médico